South & Central America Viral Vector Manufacturing Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South and Central America Viral Vector Manufacturing Market size is expected to reach US$ 85.6 Million by 2031 from US$ 32.6 Million in 2024. The market is estimated to record a CAGR of 14.9% from 2025 to 2031.

Executive Summary and South and Central America Viral Vector Manufacturing Market Analysis:

South & Central America represent a growing yet still developing market in viral vector manufacturing, characterized by a mix of emerging biotechnology hubs and evolving healthcare landscapes. Countries such as Brazil, Argentina, and Mexico are at the forefront, with increasing government and private sector initiatives aimed at advancing gene therapy research and manufacturing capabilities. The region benefits from a relatively young and expanding biotech workforce and a growing number of academic and clinical institutions investing in advanced therapies. Despite economic and infrastructure challenges, efforts are underway to establish specialized viral vector production facilities and foster collaborations with international biotech firms to gain technology transfer and expertise. Brazil has launched the world's largest mosquito biofactory, Wolbito do Brasil, in Curitiba to combat dengue fever. The facility produces mosquitoes infected with Wolbachia bacteria, which prevents the transmission of dengue, Zika, and Chikungunya viruses. This initiative aims to protect ~140 million Brazilians over the coming years by releasing infected mosquitoes into high-incidence areas, thereby suppressing virus transmission.

South & Central America Viral Vector Manufacturing Market: Strategic Insights

South and Central America Viral Vector Manufacturing Market Segmentation Analysis:

• By Type, the South and Central America Viral Vector Manufacturing Market is segmented into Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others. The Adenoviral Vectors segment dominated the market in 2024.
• By Disease Indication, the South and Central America Viral Vector Manufacturing Market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. The Cancer segment dominated the market in 2024.
• By Application, the South and Central America Viral Vector Manufacturing Market is segmented into Therapeutics Development, Vaccine Development, and Research. The Therapeutics Development segment dominated the market in 2024.
• By End User, the South and Central America Viral Vector Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CDMOs and CROs, and Research Institutes. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

South & Central America Viral Vector Manufacturing Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Viral Vector Manufacturing Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South and Central America Viral Vector Manufacturing Market Outlook

Digitalization and Data-Driven Manufacturing are rapidly transforming the viral vector manufacturing industry by enabling higher efficiency, improved product quality, and faster time-to-market for gene and cell therapies. Traditional viral vector production relies heavily on manual interventions, which can introduce variability, increase contamination risk, and limit scalability. Digital solutions-ranging from real-time process monitoring to advanced analytics-are addressing these challenges by integrating automation, data collection, and predictive control into every stage of manufacturing. One key component is the use of real-time sensors and process analytical technologies (PAT) that continuously monitor critical parameters such as pH, dissolved oxygen, temperature, and viral titer. This enables operators to detect deviations immediately, reducing batch failures and ensuring consistent product quality. Coupled with automated control systems, adjustments can be made dynamically without halting production, improving yield and reproducibility. critical trend is the application of AI and machine learning algorithms to analyze historical and real-time data. These tools can optimize upstream and downstream processes, predict process bottlenecks, and recommend interventions before issues occur. For example, AI models can forecast viral vector titers, optimize transfection efficiency, or improve purification performance, resulting in faster process development and lower operational costs. Digitalization also enables end-to-end traceability, from raw material sourcing to final fill-finish, which is crucial for regulatory compliance and quality assurance. Cloud-based platforms and centralized data management allow seamless integration across multiple manufacturing sites, facilitating scalability and enabling global production networks to operate harmoniously. In addition, digital twins-virtual replicas of production processes-are being adopted to simulate and optimize viral vector manufacturing at scale, reducing the need for trial-and-error experimentation and accelerating time-to-clinic.

South and Central America Viral Vector Manufacturing Market Country Insights

By country, the South and Central America Viral Vector Manufacturing Market is segmented into Brazil, Argentina, and the Rest of South and Central America. Brazil held the largest share in 2024.

Brazil has emerged as a leading force in viral vector manufacturing and advanced therapies in Latin America. Several recent regulatory, institutional, and collaborative developments have strengthened its position. In March 2024, ANVISA (Brazil's regulatory agency) approved Roctavian (valoctocogene roxaparvovec), a gene therapy product for severe hemophilia A, marking a milestone as Brazil's first regulatory approval for an in vivo viral vector gene therapy of that kind. Additionally, the Fundação Oswaldo Cruz (Fiocruz), especially its Bio-Manguinhos unit, has entered into a partnership with the non-profit Caring Cross to develop local manufacturing capacity of CAR-T cell therapies and associated lentiviral vectors. This collaboration aims to produce these high-complexity vectors for clinical development in oncology, infectious diseases, including HIV, and genetic diseases. Moreover, Brazil has been increasing its adoption of automation in cell and gene therapy manufacturing. For example, Terumo Blood & Cell Technologies is expanding its automated manufacturing platforms into Brazil, which can help improve efficiency and reduce costs.

South and Central America Viral Vector Manufacturing Market Company Profiles

Some of the key players operating in the market include Charles River Laboratories International Inc, Novartis AG, Catalent Inc, Lonza Group AG, Merck KGaA, GenScript Biotech Corporation, Takara Bio Inc, FUJIFILM Holdings Corp, WuXi AppTec Co., Ltd., and Thermo Fisher Scientific Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South and Central America Viral Vector Manufacturing Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise